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Abstract
Urinary tract infection is one of the most common cause of infection in newborns. Obtaining a urinary tract infections
(UTIs) diagnosis just on the basis of the clinical findings is frequently difficult, however, being the pediatrician’s goal to
reduce the risk of renal scarring, a prompt diagnosis and treatment is of extreme importance. The key instrument for the
diagnosis of UTIs is represented today by urine culture. However, in reality, the caregivers and investigators are increasingly
demanding fast and cheap methods for a rapid and effective diagnosis.
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Introduction
The urinary tract infections (UTIs) are so far the leading
cause of severe bacterial infections in infants and young
children. Population-based studies showed that 3–7% of
girls and 1–2% of boys have had at least one UTI by 6 years
of age [1].
The UTI location may be strictly limited to the bladder,
involving one or both kidneys, or cover both sites. Usually
those involving just the bladder (cystitis) are not consid-
ered severe bacterial infections despite leading to signifi-
cant morbidity. On the contrary, urinary infections with
kidney involvement by acute pyelonephritis (APN) can
cause acute renal morbidity and lead to scarring with
consequent hypertension, and chronic renal disease [2]. All
newborns and infant who suffered from APN are at higher
risk of developing UTI recurrences with cystitis episodes in
adult life. In particular, females with renal scarring
continued to have a high proportion of pyelonephritic
recurrences after 10 years of age, implying that they risk
progressive renal disease and should be closely followed
into adulthood [3].
Clinical assessment
During the first month of life, the symptoms of infection
may be nonspecific with low or no fever in about one-half
of the cases. Newborns and infants aged 0–2 months with
APN have no symptoms localized to the urinary tract
rather nonspecific one as: fever, poor feeding, failure to
thrive, prolonged jaundice and severe systemic illness; as
a result, the UTI is usually discovered as part of an
evaluation for neonatal sepsis. A subnormal or only
slightly elevated body temperature or symptoms such as
apathy, anorexia, grayish color, and body tenderness can
indicate a serious infection. Diagnosis of APN using
clinical and laboratory parameters is unreliable in children
particularly those less than 2 years. This may lead to the
young patients to be at higher risk for renal injury since
the lack of localizing signs, associated with intrinsic low
immunitary defences, delays the beginning of antimicro-
bial drugs [2,4].
The 1999 American Academy of Pediatrics (AAP)
practice parameter recommended that UTI should be
considered in any child younger than 2 years of age with
unexplained fever. UTI has accounted for febrile presenta-
tions in 7.5% of infants58 weeks, 5.3% of infants51 year,
and 4.1% of children 52 years [5].
The Pediatric Research in Office Settings (PROS)
Network of the AAP study showed UTI in 9% of febrile
infants53 months and 10% of these had bacteraemia.
It must be stressed that a recent study showed urinary
candidosis infection without extra-renal infection in term
babies with congenital abnormalities and in preterms
admitted in Neonatal Intensive Care Units was associated
with renal parenchymal disease and extra-renal dissemina-
tion. The overall mortality rate occurred in 1/3 of the
cases [6].
Risk factors
The UTIs incidence in infants approximately ranges from
0.1% to 2.0% in all newborn infants to 20% in preterm and
at risk neonatal population (i.e. low-birth-weight infants)
[7,8]. During the first months of life, there were many boys
than girls having UTIs, predominantly without high fever;
after 6 months of life, girls were prevalent [9].
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Differently by previous reports it has been recently
underlined that breastfeeding does not protect against
urinary tract infection in the first 3 months of life, but
vitamin D supplementation increases the risk by 76% [10].
Febrile UTI is considered the most common serious
bacterial infection occurring in infancy and early childhood
in the developed world. About 10–30% of children with
febrile UTIs developed renal scarring. This is actually
thought to be a risk factor also for hypertension and renal
insufficiency in the longer term [11]. The most important
end point, since long-term medical consequences (protei-
nuria, hypertension, and chronic kidney damage) is
generally associated with the presence of renal parenchy-
mal damage.
Vesico-ureteric reflux (VUR) has been considered for
many years as risk factors for APN in young children.
Therefore, the prevalence of VUR was similar among
children with and without UTI and decreased with
increasing age [12]. However, only renal scarring assessed
by renal scintigraphy and not VUR (even if high-grade and
bilateral) was a predictor of early recurrent UTI [13].
Thus, the occurrence of VUR among children without
UTI was found significantly higher than traditional
estimates. Finally, the role of VUR in establishing renal
scarring has been reappraised and some renal parenchymal
abnormalities associated with VUR are noninfectious but
congenital or prenatal in origin.
In retrospective studies, circumcision in males was
associated with a 10-fold reduction in the incidence of
having a UTI during the first year of life. Circumcision
prevented recurrent symptomatic UTI in a randomized
trial [14]. Therefore, a recent study has, however, showed a
higher rate of UTI in male infants during the post-
circumcision period, especially in those made in the
traditional way than performed in hospital due to lack of
sanitary control [15].
Recent advances in genetics have suggested that a
deregulation of candidate genes (HSPA1B, CXCR1 & 2,
TLR2, TLR4, TGF-b1 genes) in humans may predispose
patients to recurrent UTIs [16].
Laboratory diagnosis
Until now, the gold standard for the diagnosis of UTI has
always been considered the urine culture collected under
sterile conditions (e.g. suprapubic aspiration, or ‘in-and-
out’ catheterization). Therefore, in infants and small
children urine is mostly obtained from a bag sampling. A
single bag specimen should not be relied on for the
diagnosis of UTI, even if there is pure growth of more than
100,000 UFC/ml urine.
Because culture results are not available for at least 24 h,
there has been considerable interest in evaluating tests that
may predict the results of the urine culture so that
appropriate therapy can be initiated at the first encounter
with the symptomatic patients. The tests that have received
the most attention are urine microscopy for leukocytes and
bacteria, and biochemical analyses for leukocyte esterase
and nitrite that can be assessed rapidly by dipstick. A
dipstick negative for leukocyte esterase and nitrite, or
microscopic analysis negative for pyuria and bacteriuria of
a clean voided urine, bag, or nappy/pad specimen may
reasonably be used to rule out UTI, avoiding the need for
further investigations [17]. Therefore, comparing micro-
scopy and urine dipstick testing, using bacterial colony
count on urine culture showed no significant difference
between the two methods [18].
In the recent years serum procalcitonin, a marker of
bacterial disease, has been tested to predict the level of
infection in newborns with sepsis and in children with UTI
[19–22]. Procalcitonin seems to be a valid biological
marker, with an acceptable sensitivity and specificity,
which predicts a renal involvement of the infection
(pyelonephritis), in comparison with the low specificity of
C-reactive protein. Procalcitonin also seems to be corre-
lated with the degree of involvement at the moment of
diagnosis of febrile UTIs and with scarring. This measure-
ment could be useful for the treatment of children with
febrile UTIs, allowing prediction of patients at risk of
permanent parenchymal renal lesions. Although the
number of studies published is limited, procalcitonin has,
however, demonstrated some specific characteristics that
make it more reliable than C-reactive protein in high-
lighting renal lesions during UTIs. These are, firstly, the
velocity with which it is induced by the infectious stimulus,
which increases somehow its high negative predictive
value; secondly, the grater specificity compared with
C-reactive protein in detecting renal involvement
during febrile UTIs; and lastly, but maybe the most
interesting aspect, even though documented in only two
studies, is the progressive increase of its blood concentra-
tion correlated with the increase of the renal lesion’s
entity. In conclusion, for the time being, a value of
procalcitonin 40.5 ng/ml can be considered an accurate
and sufficiently reliable new biological marker to be used in
clinical treatment of febrile UTIs and to predict renal
parenchymal involvement, as also evidenced by Tc-99m
dimercaptosuccinic acid (DMSA) scintigraphy [23]. Pro-
mising results are expected with metabolomic studies on
urine of newborn and infants with renal disease compared
with controls [24].
Imaging and UTI
Various imaging investigations (including ultrasonography,
voiding cystography, and technetium-99m-DMSA scinti-
graphy) after a first febrile UTI have been widely
recommended, with the objective of identifying pathologic
malformations and/or risk factors that, if not appropriately
diagnosed and managed, might lead to additional infec-
tions and ongoing renal parenchymal damage. Evidence of
the value of these imaging studies in changing management
approaches or affecting subsequent outcomes is limited,
especially today, given the questionable role of antibiotic
prophylaxis since some authors have reported that long-
term antibiotic prophylaxis does not fully prevent UTI or
scarring, that antibiotic-related adverse events are known
to occur, and that the incidence of APN does not increase
in spite of prophylactic antibiotic cessation [25].
In the past, most studies concentrated on the prevalence
of urologic abnormalities and not the effect that early
detection and management of anomalies might have on
preventing subsequent renal parenchymal damage. Renal
ultrasonography and renal scanning at the time of the acute
illness are of limited value, because they do not provide
information that modifies management. Up to now there is
no firm evidence of using routine imaging for children
under 2 years old and for the one of 2 or more with an
initial UTI it is still not recommended, in fact the exact
role of routine imaging studies after the diagnosis of a first
febrile UTI in 309 children 1–24 months of age it is still to
be established. However, children 2–5 old with an initial
UTI should be monitored and investigated further if they
experienced a second UTI [26].
























































A test for the localization of UTI as an initial step in the
investigation of these patients would allow the exclusion of
all children with a lower UTI from further investigation.
A non-invasive test would be desirable. Acute Tc-99m-
DMSA scintigraphy remains the reference standard for the
localization of UTI. Therefore, these scans are expensive,
invasive, and incur a radiation load. However, there is
insufficient evidence to recommend any further investiga-
tion routinely: in the absence of any effect on patient
outcome, universal imaging (for example, VCUG for reflux
or DMSA scintigraphy for renal scarring) cannot be
justified. The decision on whether or not to perform these
examinations should be made on individual patient basis.
Actually, many authors suggest that VCUG should be
reserved for those children who have been deemed to
require further investigation, after the demonstration of
an abnormal DMSA scan and abnormal urinary tract by US.
Treatment
Pharmacotherapy is the cornerstone of the treatment of
UTI in newborns and children. Any recommendation
about (initial) antibiotic treatment should be regularly
updated and adapted to local resistance profiles and to
economical factors in different health systems [27].
In sick newborns and young infants, antibiotics are
generally used empirically prior to availability of urine or
blood culture results. Based on local bacterial ecology and
the known causative organisms for septicemia and urinary
tract infection, ampicillin and an aminoglycoside (e.g.
gentamicin) are used parenterally. Gentamicin is exten-
sively used and increasingly given once a day in newborn
infants. This dosing regime increases peak concentrations
of the drug without increasing plasma trough levels and
nephrotoxicity. However, there is a trend to use third and
fourth generation cephalosporins such as, cefotaxime,
ceftazidime, cefepime. These drugs are excreted mainly
via renal elimination, and like most drugs, the plasma
elimination of these agents in newborns is prolonged
compared to that of the adults and older children.
Therefore, dosing regimens are adjusted for newborns of
various fetal and postnatal maturities. It is strictly
forbidden the use of cefriaxone in newborns [27–30].
The benefits demonstrated after the beginning of
antibiotic treatment were the eradication of infection in
all cases and the time to resolution of fever.
In older infants and children, Doganis et al. reported
that delayed treatment over 24 h did not seem to increase
the risk of renal scars. In fact frequency of scarring: 11 out
of 24 infants treated in the first 24 h versus 28 out 52
treated later [31].
Moreover, no significant difference in the incidence of
scarring was observed in relation to the selection and route
of administration of antibiotics [32]. Despite some limita-
tions, the first concerning exact time of the onset of
infection, this study reflects accurately the clinical situation
in which a child presents as febrile and unwell, with
symptoms suggesting APN. At such a time, with the
inflammatory process well established, it seems that
antibiotics do little to reduce scarring. They though it is
possible to advise a less-urgent approach for children with
fever who appear otherwise well, even if there is a risk of
recurrent UTI.
This topic is controversial and there is still a debate in
the literature: some authors suggest in their title that early
antibiotic treatment of pyelonephritis in children is still
mandatory [33].
Coulthard et al. report that being febrile or unwell
during a UTI does not predict the development of scars,
but prompt treatment appears to prevent scarring in
children with VUR [34].
Numerous studies have addressed the treatment of APN
in children, comparing different antibiotics and different
modes and durations of administration [35,36]. In quite all
of those studies, the outcomes (kidney damage) are similar
in the various arms, leading to the assumption that all
treatments are equally effective in reducing scarring
secondary to APN.
In an interesting paper entitled ‘Urinary tract infections
revisited’ Godaly and Svanborg suggest a potential tailored
management of pediatric UTI in the next future, consider-
ing bacterial virulence and host immune response:
standard antibiotic treatment should be reserved only to
patients with high bacterial virulence and high immune
response [37].
The use of prophylactic antibiotic following UTI,
particularly in young children with VUR, has been a
common practice for decades. However, at such a time,
with the inflammatory process well established, it seems
that antibiotics do very little to reduce scarring [38].
Additional research is needed to explore other avenues
of therapy, such as the use of steroids or other anti-
inflammatory agents, and to evaluate the role of genetic
factors that may predispose patients to scar formation [38].
Conclusion
Early treatment of UTI, namely febrile, is considered
strictly mandatory in newborns. In infants and young
children early treatment of APN seems to have no
significant effect on the incidence of subsequent renal
scarring; antimicrobial prophylaxis seems to have little
effect in preventing UTI recurrences and the exact role of
the imaging after a first UTI is still debated.
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